🇺🇸 FDA
Patent

US 9309279

Macrocyclic hepatitis C serine protease inhibitors

granted A61PA61P1/16A61P31/12

Quick answer

US patent 9309279 (Macrocyclic hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/16, A61P31/12, A61P31/14, A61P31/18